Is the United Kingdom (UK) medicines pricing policy failing patients? The impact of terminated National Institute for Health and Care Excellence (NICE) appraisals for multi-indication products on patients

Helen Mitchell, Qian Xin, Jack Hide, Clement Halin, Swarali Sunil Tadwalkar, Sabera Hashim, Richard Hudson
doi: https://doi.org/10.1101/2024.08.06.24311489

Article Information

doi 
https://doi.org/10.1101/2024.08.06.24311489
History 
  • August 7, 2024.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.

Author Information

  1. Helen Mitchell1,*,
  2. Qian Xin2,3,
  3. Jack Hide2,
  4. Clement Halin1,
  5. Swarali Sunil Tadwalkar2,
  6. Sabera Hashim2 and
  7. Richard Hudson1
  1. 1Sanofi, Reading, UK
  2. 2Clarivate, London, UK
  3. 3University of Bristol, Bristol, UK
  1. ↵* Corresponding author; email: helen.mitchell{at}sanofi.com
Back to top
Posted August 07, 2024.
Download PDF

Supplementary Material

Data/Code
Email
Is the United Kingdom (UK) medicines pricing policy failing patients? The impact of terminated National Institute for Health and Care Excellence (NICE) appraisals for multi-indication products on patients
Helen Mitchell, Qian Xin, Jack Hide, Clement Halin, Swarali Sunil Tadwalkar, Sabera Hashim, Richard Hudson
medRxiv 2024.08.06.24311489; doi: https://doi.org/10.1101/2024.08.06.24311489
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area